Profil
Martin Lauriot Prévost is the founder and current Chairman of Ozyme SAS, which is founded in 1984.
He is also currently a Member-Supervisory Board at Nosopharm SAS.
Aktive Positionen von Martin Lauriot Prévost
| Unternehmen | Position | Beginn |
|---|---|---|
Ozyme SAS
 Ozyme SAS BiotechnologyHealth Technology Ozyme SAS is a distributor of reagents, instrumentation, and services in the fields of cellular biology, immunology, and molecular biology. The private company is based in Montigny-le-Bretonneux, France. and has subsidiaries in France. The French company was founded in 1984 by Martin Lauriot Prévost. | Gründer | 01.01.1984 |
Nosopharm SAS
 Nosopharm SAS Pharmaceuticals: MajorHealth Technology Nosopharm SAS operates as a biotechnology company. It develops an anti-infective drug platform that is based on the medicinal chemistry of a novel antibiotic class used to cure life-threatening multi-resistant hospital-acquired infections. The company was founded by Philippe Villain-Guillot and Maxime Gualtieri in February 2009 and is headquartered in Nimes, France. | Direktor/Vorstandsmitglied | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Ozyme SAS
Ozyme SAS BiotechnologyHealth Technology Ozyme SAS is a distributor of reagents, instrumentation, and services in the fields of cellular biology, immunology, and molecular biology. The private company is based in Montigny-le-Bretonneux, France. and has subsidiaries in France. The French company was founded in 1984 by Martin Lauriot Prévost. | Health Technology |
Nosopharm SAS
Nosopharm SAS Pharmaceuticals: MajorHealth Technology Nosopharm SAS operates as a biotechnology company. It develops an anti-infective drug platform that is based on the medicinal chemistry of a novel antibiotic class used to cure life-threatening multi-resistant hospital-acquired infections. The company was founded by Philippe Villain-Guillot and Maxime Gualtieri in February 2009 and is headquartered in Nimes, France. | Health Technology |
